AGM Statement

RNS Number : 3773T

Proteome Sciences PLC

17 July 2015

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

AGM Statement

17^th July, 2015.  Our core businesses are performing well and the big increase in demand recently reported in biomarker services continues to grow with four further SysQuant^® contracts secured since the preliminary results at the end of May.  With our facilities running at full capacity in 2015 the process is underway to add further mass spectrometry equipment and output in the second half of the year to satisfy this demand and to significantly increase the scale of the biomarker services division.

We are very pleased to be selected to make 3 oral presentations at the Alzheimer's Association International Conference (AAIC) in Washington DC later this week including SysQuant^® and TMT calibrator™ data and results in AD where we will be continuing discussions with prospective licensees for our CK1d compounds.

With the current buoyant background and a good pipeline with excellent prospects the directors expect to see strong growth in revenue and news flow into 2016.

- Ends -

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Operating Officer	Tel: [phone]
Geoff Ellis, Finance Director
Nominated Adviser
Cenkos
Mark Connelly/Callum Davidson finnCap Geoff Nash	Tel: [phone] Tel : [phone]
Public Relations
IKON Associates	Email: [e-mail]
Adrian Shaw	Tel: [phone]
	Mobile [phone]

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services^™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.

 

END

 

 

AGMRRMLTMBABMFA